Although EGFR is expressed at high levels in head and neck squamous cell carcinomas (HNSCCs) and mutations are extremely rare, monotherapy with EGFR inhibitors has shown limited success. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.